Gao Dongkai, Zhou Zumo, Chen Lin, Zheng Jun, Yang Jinna
Department of Infectious Diseases, Zhuji People's Hospital of Zhejiang Province, No. 9 Jianmin Road, Taozhu Street, Zhuji City, Shaoxing City, Zhejiang Province, 311800, China.
Hepatobiliary Surgery, Zhuji People's Hospital of Zhejiang Province, Zhuji City, Shaoxing City, Zhejiang Province, China.
BMC Cancer. 2025 Mar 11;25(1):435. doi: 10.1186/s12885-025-13808-7.
Although Cell growth regulator with EF-hand domain 1 (CGREF1) has been predicted to be upregulated in multiple cancer types, its definitive function role in carcinogenesis, particularly in hepatocellular carcinoma (HCC), remains poorly characterized.
Comprehensive bioinformatics analysis was initially conducted using the University of ALabama at Birmingham CANcer data analysis Portal (UALCAN) and Gene Expression Profiling Interactive Analysis (GEPIA) databases to investigate CGREF1 mRNA expression patterns in HCC tissues and their clinical correlation with patient survival outcomes. Experimental validation was subsequently performed through real-time quantitative polymerase chain reaction (RT-qPCR), immunohistochemistry (IHC), and Western blot techniques. Functional characterization studies employing genetic knockdown and overexpression models in HCC cell lines demonstrated CGREF1's regulatory effects on malignant phenotypes, as evidenced by 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay, colony formation assay and Transwell migration and invasion assays. were adopted to investigate the role of CGREF1 in the proliferation, invasion, and migration of HCC cells. Mechanistic investigations integrating bioinformatics predictions with Western blot analysis revealed CGREF1 mediated-modulation of the Wnt/β-Catenin signaling axis, elucidating its molecular underpinnings in HCC progression.
The results demonstrated that CGREF1 is highly expressed in HCC tissues, and HCC patients with elevated CGREF1 expression exhibited significantly shorter survival times. Upregulation of CGREF1 promoted the proliferation, migration, and invasion of HCC cells, whereas inhibition of CGREF1 expression suppressed these phenotypes. Mechanistically, CGREF1 activates the Wnt/β-Catenin signaling pathway through the upregulation of eukaryotic translation initiation factor 3 H subunit (EIF3H). Furthermore, partial inhibition of EIF3H attenuated the effects of CGREF1 overexpression on the proliferation, migration, and invasion of HCC cells.
CGREF1 is upregulated in HCC and acted as an oncogene through the CGREF1/EIF3H/Wnt/β-Catenin signaling axis. These findings suggest that CGREF1 may emerge as a potential therapeutic target for HCC.
尽管预测含EF手结构域的细胞生长调节因子1(CGREF1)在多种癌症类型中上调,但其在致癌过程中,尤其是在肝细胞癌(HCC)中的明确功能作用仍不清楚。
最初使用阿拉巴马大学伯明翰分校癌症数据分析门户(UALCAN)和基因表达谱交互式分析(GEPIA)数据库进行综合生物信息学分析,以研究CGREF1 mRNA在肝癌组织中的表达模式及其与患者生存结果的临床相关性。随后通过实时定量聚合酶链反应(RT-qPCR)、免疫组织化学(IHC)和蛋白质印迹技术进行实验验证。在肝癌细胞系中采用基因敲低和过表达模型进行功能特性研究,通过3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐(MTT)法、集落形成试验以及Transwell迁移和侵袭试验证明了CGREF1对恶性表型的调节作用。采用这些试验来研究CGREF1在肝癌细胞增殖、侵袭和迁移中的作用。将生物信息学预测与蛋白质印迹分析相结合的机制研究揭示了CGREF1介导的Wnt/β-连环蛋白信号轴调节,阐明了其在肝癌进展中的分子基础。
结果表明,CGREF1在肝癌组织中高表达,CGREF1表达升高的肝癌患者生存时间显著缩短。CGREF1的上调促进了肝癌细胞的增殖、迁移和侵袭,而抑制CGREF1表达则抑制了这些表型。机制上,CGREF1通过上调真核翻译起始因子3 H亚基(EIF3H)激活Wnt/β-连环蛋白信号通路。此外,部分抑制EIF3H减弱了CGREF1过表达对肝癌细胞增殖、迁移和侵袭的影响。
CGREF1在肝癌中上调,并通过CGREF1/EIF3H/Wnt/β-连环蛋白信号轴发挥癌基因作用。这些发现表明,CGREF1可能成为肝癌的潜在治疗靶点。